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Objective: We aim to report intra-arterial thrombectomy transfer metrics for ische-
mic stroke patients that were transferred to hub hospitals for possible intra-arterial
thrombectomy in multiple geographic regions throughout the state of Texas and to
identify potential barriers and delays in the intra-arterial thrombectomy transfer
process. Method: We prospectively collected data from 8 participating Texas com-
prehensive stroke/thrombectomy capable centers from 7 major regions in the State
of Texas. We collected baseline clinical and imaging data related to the pre-transfer
evaluation, transfer metrics, and post-transfer clinical and imaging data. Results: A
total of 103 acute ischemic stroke patients suspected/confirmed to have large vessel
occlusions between December 2016 to May 2019 that were transferred to hubs as
possible intra-arterial thrombectomy candidates were enrolled. A total of 56 (54%)
patients were sent from the spoke to the hub via ground ambulance with 47 (46%)
patients traveling via air ambulance. The median spoke arrival to hub arrival time
was 174 min, median spoke arrival to departure from spoke was 131 min, and
median travel time was 39 min. The spoke arrival time to transfer initiation was
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68 min. CT-perfusion obtained at the spoke and earlier initiation of transfer were
statistically associated with shorter transfer times. Conclusion: Transfer of intra-arte-
rial thrombectomy patients in Texas may take over 4 h from spoke arrival to hub
arrival. This time may be shortened by earlier transfer initiation and acceptance.
Key Words: Ischemic stroke—Endovascular thrombectomy—Mechanical
thrombectomy—Transfer—Large vessel occlusion
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction
Treatment with intravenous tissue plasminogen activa-
tor (IV t-PA) has been established as an effective treatment
for acute ischemic stroke patients treated within the first
few hours of symptom onset.1 Although the treatment
window for effectiveness was extended from 3 to 4.5 h, it
has been clearly demonstrated that earlier treatment is sta-
tistically associated with a higher likelihood of a better
outcome.2,3 In addition, intra-arterial therapy (IAT) has
been demonstrated in multiple trials to improve outcomes
in acute stroke patients when treated within 6 h and if per-
fusion imaging is obtained, 6 to 24 h.4 This had led the
American Heart/American Stroke Association to not only
release guidelines recommending endovascular proce-
dures for selected patients but also organize stroke sys-
tems of care to facilitate the delivery of this treatment.5
Unfortunately, not all patients eligible for endovascular
therapy present to facilities capable of delivering endovascu-
lar treatment and thus, often need to be transferred to com-
prehensive stroke centers/thrombectomy capable (CSC/
TC) centers for the procedure to be performed. Specifically,
for Texas, which is a large state with a wide geographic dis-
tribution of over 29 million residents, quick access to a center
that can deliver this robust treatment is essential. The trans-
fer process is complex and often involves multiple teams of
physicians and administrative personnel to coordinate the
transfer of the patient. The complexity can often lead to
delays in arrival of the patient to the hub and possibly lead
to suboptimal outcomes or at times exclude the patient from
the procedure due to the limited therapeutic window or pro-
gression of ischemic injury.
Currently, there are no standard time metrics recom-
mended for the IAT transfer process. We therefore aim to
describe in this study, Intra-arterial Transfer Metrics
Study (IAT-TiMeS), the current landscape of IAT transfer
time metrics and characteristics at multiple Texas CSC/




We prospectively collected data from 8 participating CSC/
TCs from 7 major regions in the State of Texas. All CSCs
were designated as such by national accrediting organiza-
tions. We allocated enrollment of patients at each site in order
to balance the data according to the typical case volume and
not be heavily skewed by centers or regions (Fig. 1).
Study population
All patients that were initially evaluated at a spoke site
and transferred to a participating Texas CSC/TC (hub)
for higher level or care, specifically for evaluation of IAT,
were included. Enrollment at each hub was given a pre-
specified target. We aimed to enroll a total of 100 patients
in this observational study.
Data Collection
Baseline clinical and imaging data at the spoke, transfer
metrics, and clinical and imaging data at the hub were col-
lected. The study enrollment period began in December
2016 and ended in May 2019; we followed a rolling enroll-
ment approach as sites were initiated. The hub hospital
sites included Memorial Hermann  Texas Medical Cen-
ter in Houston, Texas (20 patients), UTHealth Science
Center at San Antonio—University Hospital (5 patients),
Texas Tech University Health Science Center in Lubbock,
Texas—University Medical Center (9 patients), Texas
Tech University Health Science Center in El Paso, Texas—
Sierra Medical Center and University Medical Center (9
patients), UTHealth Science Center at Austin, Seton—
Seton Medical Center and University Medical Center
Brackenridge (20 patients), UT Southwestern Medical
Center in Dallas, Texas (10 patients), Baylor Scott and
White Medical Center in Dallas, Texas (10 patients) and
Valley Baptist Medical Center in Harlingen, Texas (20
patients). Each participating hub site is part of the Lone
Star Stroke Clinical Trial Network. IRB approval was
obtained at all participating hub sites for this study.
In total, we had 46 spokes sites that transferred patients
for IAT evaluation at the hub sites. Thirty-two of the 46 sites
were designated as primary stroke centers and the remain-
ing 14 had no stroke center designation and were a mix of
community hospitals and free-standing emergency centers.
Statistical analysis
Descriptive statistics (mean, standard deviation, median,
quantile, frequency, percentage) were provided for demo-
graphic and clinical variables. Wilcoxon rank sum test was
used to compare the spoke arrival to hub arrival time
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between groups such as sex, telemedicine use, IV-tPA use,
etc. For groups with more than two levels such as race, Krus-
kal-Wallis test was used instead. Spearman method was
used to evaluate correlation between the spoke arrival to
hub arrival time and other continuous variables. All statisti-
cal analyses were performed by using the SAS software (ver-
sion 9.4, the SAS Institute, Cary, NC).
Results
A total of 103 patients were enrolled from 46 spokes at 9
hubs into IAT-TiMeS in the study period and included in
the analysis (Table 1a). The mean age of the study group
was age 67 years with 49% female. The majority of the
patients were white (79%); African and Asian Americans
made up approximately 15% of the enrolled patients and
about a third of the patient sample were Hispanic. The
median NIHSS at the spoke was 14.
Of the 103 patients, 66 (64%) received IV-tPA
(Table 1b) at the spoke hospital prior to transfer and 59
(57%) were managed via telemedicine at the spoke hos-
pital prior to transfer to the hub. The median door to
needle time was 53 min. Over half of the patients (52%)
had CT-angiography of the brain performed at the
spoke, but only 12 (11.7%) had CT-perfusion of the
brain performed at the spoke.
Upon arrival to the hub, 49 patients (47%) (Table 1c)
underwent further imaging with a combination of CT,
CT-angiography, and/or CT-perfusion of the brain. Of
the 37 patients (69%) that had CT-perfusion performed,
28 (78%) utilized automated CT-perfusion software. Only
11 patients (11%) underwent MRI upon arrival to the hub
prior to thrombectomy decision.
In total, 79 of the 103 transferred patients underwent a
cerebral angiogram at the hub after arrival and 67 (65%)
had subsequent thrombectomy performed. Only 3 (3%)
symptomatic intracerebral hemorrhage (ICH) were docu-
mented with median length of stay of 5 days (Table 1d).
A total of 56 (54%) patients were sent from the spoke
to the hub via ground ambulance with 47 (46%) patients
Fig. 1 Study hub sites.
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traveling via air ambulance (Table 2). The median
arrival from spoke to hub time was 174 min, and
median travel time was 39 min. The median spoke
arrival time to transfer initiation was 68 min. The
median spoke arrival time to departure from spoke
(door-in to door-out) was 131 min.
The spoke arrival to hub arrival time was not statistically
associated with age, sex, race, telemedicine use, IV-tPA use,
CT-angiography performed at spoke, or mode of transfer.
We did find that patients who underwent CT-perfusion at
Table 1a. Baseline characteristics of transfer cohort (n = 103).
Baseline Demographics
Mean Age (SD) 67 (57.0, 78.0)
Female, N (%) 49 (48)
Race, N (%)
White 81 (79)
African American 13 (13)
Asian 2 (2)
Other/Not Reported 7 (7)
Ethnicity, N (%)
Hispanic or Latino 33 (32)
Not Hispanic or Latino 65 (63)
Not reported 5 (5)
Past Medical History, N (%)
Prior Ischemic Stroke 15 (15)
Prior Hemorrhagic Stroke 2 (2)
Prior TIA 8 (8)
Hypertension 73 (71)
Congestive Heart Failure 9 (9)
Atrial Fibrillation 26 (25)
Hypercholesterolemia 28 (27)
Diabetes 34 (33)








Performed at spoke, N (%) 59 (57)
Door to TM Page Time, Median in
Minutes (Q1,3)
18 (5, 36)
TM Page Time to Camera Time,
Median in Minutes (Q1,3)
9 (6, 12)
NIHSS at Spoke, Median (Q1,3),
N = 75
14 (8, 19)
NIHSS at Hub, Median (Q1,3), N = 88 12 (6, 19)
Premorbid mRS, (%) N = 59
0-No Symptoms 42 (41)
1-No Significant disability 6 (5.8)
2-Slight disability 3 (2.9)
3-Moderate disability 7 (6.8)
4-Moderate disability 1 (1)
Not reported 44 (43)
Table 1c. Imaging.
Imaging at Spoke








Not Reported 5 (5)
Imaging at Hub
Cerebral angiogram performed at hub, N (%)
Yes 79 (77)
No 24 (23)








































ASPECTS, Median (Q1-3), N = 36 8 (7,9)
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the spoke had statistically significant shorter transfer times
to the hub (median: 120.5 min vs 185 min, Z statistic = -
2.229, p = 0.028). Earlier transfer initiation times were also
significantly associated with shorter transfer times (Spear-
man correlation coefficient = 0.79, p < 0.0001). Interestingly,
we did find a positive correlation between lower transfer
times and lower 90-day mRS with Spearman correlation of
0.39 (p = 0.005).
We also analyzed transfer times during on vs off hours
(on hours: 8a-5p; off hours: 5p-8a) and weekdays vs week-
end transfers times. We found no statistical correlation
with this analysis.
Discussion
Intra-arterial thrombectomy has been one of most
impactful acute ischemic stroke treatments developed
in the last decade. However, many patients that are
found to have large vessel occlusion (LVO) still need to
be transferred to thrombectomy capable centers in
order to have the procedure performed. The transfer
process can be tedious, and the complex process can be
fraught with delays. For example, the patient first needs
to be evaluated at the spoke either by the local emer-
gency room team, remote telemedicine team, or local
neurologist to determine treatment eligibility that
includes IV-tPA. Neuroimaging such as CT brain and
when indicated CT-angiography/CT-perfusion needs
to be performed if available. Once the patient has been
identified as needing transfer, the local team then ini-
tiates the transfer by calling a CSC/TC with an accept-
ing physician. Often, this triage can be time consuming,
and if the accepting facility is full, the process needs to
start over again with another facility. Once the patient
is accepted, the patient still needs to be transported,
which can also be further opportunity for delays involv-
ing availability of air and ground transport, weather,
and other factors. Inter-hospital transfers have been
shown to delay treatment for patients requiring IAT
and impact outcomes.6
Currently, there are no practice standards for transfer
metrics regarding the IAT transfer process. We aimed
to report and describe the IAT transfer times for
patients throughout Texas in order to gain a better
understanding of the current landscape regarding IAT
transfers for the state. We found that in our population,
it took nearly 3 h (174 min) for the patients to arrive at
the hub before their evaluation for thrombectomy, and
transfer times were not impacted by IV-tPA delivery at
the spoke or mode of transfer. Patients spent over 2 h
(131 min, median, door-in to door-out) at the spoke
before departure for the hub, which is an area that
needs improvement. This confirms previous findings in
retrospective and in single center studies that door-in
to door-out time accounts for the bulk of treatment
delays. Furthermore, these studies suggest that pro-
longed door-in to door-out time is associated with
worse outcomes.7
In IAT-TiMeS, shorter transfer times were noted in
patients that underwent CT-perfusion at the spoke and with
earlier transfer initiation. We are uncertain why CT-perfu-
sion performed at the spoke was associated with shorter
transfer times but postulate that facilities equipped with CT-
perfusion may have more resources, higher stroke volumes,
and greater experience with stroke transfer processes. They
may already have in place protocols, algorithms, and estab-
lished relationships with thrombectomy centers that have
already addressed some transfer barriers. Interestingly, anal-
ysis of a late-window (624 h) thrombectomy trial suggests
Table 2. Transfer Metrics.
Mode of Transportation, N (%)
Ground Ambulance 56 (54)
Air Ambulance 47 (46)
Transfer Time Metrics, Median
n Minutes (Q1,3)
Arrival to spoke to arrival at hub,
N = 96
174 (120, 255)
Arrival to spoke to departure
from spoke, N = 79
131 (93, 187)
Departure from spoke to arrival
at hub, N = 81
39 (20, 62)
Arrival to spoke to transfer
initiation, N = 84
68 (43, 110)
Table 1d. Clinical Outcomes and Complications.







Length of Stay, Mean Days (Q1,3),
N = 103
5 (3,10)
90 day mRS, (%) N = 59
0-No Symptoms 10 (9.7)
1-No Significant disability 7(6.8)
2-Slight disability 6 (5.7)
3-Moderate disability 12 (11.7)
4-Moderate disability 9 (8.7)
5- Severe disability 5 (4.9)
6-death 14 (13.6)
Not reported 40 (38.8)
Transfer Time and Outcome Correlation
(p value)
Door to revascularization time 0.18 (0.27)
24 hour NIHSS 0.07 (0.60)
90 day mRS 0.39 (0.005)
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that there are patients who are slow progressors, where
door-in to door-out times may not negate the benefit of IAT
for stroke.8 These patients may be identified by perfusion
imaging. However, our study demonstrates that the major-
ity of patients at spoke centers do not receive perfusion
imaging. Furthermore, the late-window slow progressors
identifiable on CT-perfusion represent a small segment of
patients being transferred for IAT, maintaining the need for
optimizing door-in to door-out in general.
We also learned that the practice pattern in our popula-
tion was quite variable. Not all patients underwent
advanced neuroimaging at the spoke or even at arrival of
the hub. These variations highlight the complexity when
developing stroke systems of care, as it is often dependent
on local practice patterns and available resources. We
advocate that to shorten IAT transfer times, transfers to
the hub must be initiated as early as possible. Often times,
transfers are initiated after the patient has been fully tri-
aged with all studies and treatments delivered at the
spoke. Ideally, once the patient is suspected at the spoke
to have a LVO, possibly with a stroke severity screening
assessment, such as the VAN screening tool9, the transfer
process should be initiated.
Many emergency room physician teams at the spoke
may be reluctant to begin the transfer process until it is
certain that a transfer is required, due to the concern
that transfers may need to be cancelled. For example, if
the CT-angiography does not reveal an LVO or CT
brain shows a hemorrhage, then the transfer for IAT
may not be indicated. However, in order to streamline
the IAT transfer process, spokes should have a low
threshold to contact the accepting hubs early in the
emergency triage. Better to cancel a transfer than delay
one. Overall, our greatest impact to reduce IAT transfer
times in Texas is likely to occur by enhancing door-in
door-out protocols at spoke hospitals. In addition to
early CSC/TC notification, investing in spoke technol-
ogy with CTP and automated software may also
improve times.10
Our study has several limitations. Although our data
were gathered prospectively, the analysis was per-
formed retrospectively. The number of patients
included in the study is small and results may not be
entirely generalizable for all stroke centers throughout
the nation or for all patient populations. Also, transfer
patterns are often determined by pre-existing relation-
ships between facilities, and not by geographic proxim-
ity. Further analysis of transfer patterns and transfer
metrics based on proximity may be beneficial to mini-
mize transfer times.
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